Form 4 Filing for AEON Biopharma, Inc. - Officer Stock Acquisition

This filing details a Form 4 submission by John Bencich, Chief Financial Officer of AEON Biopharma, Inc. On April 2, 2026, Mr. Bencich acquired 754,717 shares of Class A Common Stock through a restricted stock unit award granted on April 1, 2026. The award vests over four years, with the acquisition price being $0.00, as indicated by footnote F1. This transaction is reported as a direct ownership acquisition under the ticker AEON. The filing was signed on April 3, 2026.